Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene

In conclusion, achievement of successful and maintenance of remission of P-aHUS in this patient who had limited access to Eculizumab raise the attention of the efficacy of Eculizumab at longer time intervals. However, it is time to consider conduct ing a long-term study to learn about the safety and efficacy of this approach, which may have a major financial advantage for patients.

http://link.springer.com/10.1007/s13730-019-00383-7

Source: CEN Case Reports - February 4, 2019 Category: Urology & Nephrology Source Type: research